Hypothetical thought: if Aducanumab is now in Phase IV, shouldn't the revenue coming from Aducanumab related activities be accounted for as Clinical Trials revenue?
5 Weeks until Aducanumab PDUFA date, page-38
Add CGS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.12 |
Change
0.000(0.00%) |
Mkt cap ! $191.2M | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.13 | $1.07 | $173.0K | 158.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 99324 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 10976 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| CGS (ASX) Chart |